Table 1 Clinicopathologic features of published cases with de novo acute lymphoblastic leukemia-like disease of high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements
Case (ref. n) | Age/sex | Extramedullary lesion at presentation | CNS | FAB criteria | Immunophenotype | Main cytogenetic abnormalities | FISH or gene analysis | Curative therapy | Survival | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CD10 | CD19 | CD20 | sIg | IGH-BCL2 | MYC | Â | |||||||
1 (8) | 57/F | bone | + | L3 | + | + | – | ND | t(8;22)(q24;q12a),t(14;18)(q32;q21) | NA | NA | ALL regimen | 7 mo |
2 (9) | 74/M | palate, L (cervical, pretracheal) | – | L3 | NA | + | NA | μ | t(8;22)(q24;q11),t(14;18)(q32;q21) | NA | NA | ALL regimen | 3 mo |
3 (9) | 37/M | none | – | L2 | – | + | + | IgMλ | t(8;22)(q24;q11),t(14;18)(q32;q21) | NA | NA | ALL regimen | 12 mo |
4 (9) | 73/M | none | + | L3 | + | + | + | IgMκ | t(8;22)(q24;q11),t(14;18)(q32;q21) | NA | NA | ALL regimen | 8 mo |
5 (10) | 62/M | H, S | – | L3 | + | + | + | ND | t(8;14)(q24;q32),t(14;18)(q32;q21) | NA | NA | ALL regimen | 3 mo |
6 (11) | 35/M | none | – | L3 | + | + | NA | ND | t(14;18)(q32;q21) | GR (+) | GR (+) | ALL regimen | 0.3 mo |
7 (12) | 27/M | L (IP, RP) | + | L3 | + | + | – | ND | t(8;22)(q24;q11),der(14)t(14;18)(q32;q21) | NA | NA | ALL regimen | 5 mo |
8 (13) | 67/M | none | – | L3 | NA | + | + | IgGκ | t(8;22)(q24;q11),t(14;18)(q32;q21) | NA | NA | none | 0.1 mo |
9 (14) | 71/M | none | – | L3 | −/+ | + | + | IgMλ | t(1;3;11)(q42.3;q27.1;q23.1),der(8)t(8;9)(q24.2;p13.3),t(14;18)(q32.3;q21.3),der(17)t(17;?)(p13;?) | GR (+) | GR (+) | none | 0.1 mo |
10 (15) | 36/F | IP mass | – | NA | + | + | NA | ND | t(8;22)(q24;q11),t(14;18)(q32;q21) | NA | GR (−) | ALL regimen | 3 mo |
11 (15) | 60 M | none | + | L2 | NA | NA | NA | NA | t(8;22)(q24;q11),t(14;18)(q32;q21),+der(14)t(14;18)(q32;q21) | NA | GR (−) | ALL regimen | 6 mo |
12 (16) | 40/M | GL, paravertebral mass | – | L2 | + | + | + | NA | der(6)t(6;8)(q1?;q24),add(8)(q24),der(9)t(8;9)(q24;p1?),t(14;18)(q32;q21),del(17)(p11) | NA | NA | ALL regimen | 1 mo |
13 (17) | 69/M | H | – | L3 | – | + | + | IgMκ | der(7;17)(q10;q10),+der(8)t(8;14;18)(q24;q32;q22),add(14)(q32),del(18)(q21) | GR (+) | NA | ALL regimen | 5 mo |
14 (18) | 41/F | none | – | L3 | + | + | + | NA | t(2;3)(p12;q27),del(8)(q24),t(14;18)(q32;q21) | GR (+) | GR (+) | ALL regimen | 10 mo |
15 (19) | 50/F | GL | – | L2 | + | + | + | IgMκ | t(3;4)(q27;p13),t(8;14;18)(q24;q32;q21),+ider(8)(q10)t(8;14;18)(q24;q32;q21) | GR (+) | GR (+) | ALL regimen | 0.1 mo |
16 (19) | 44/M | GL, S | + | NA | + | + | + | IgMκ | t(3;13)(q27;q14),t(8;22)(q24;q11),t(14;18)(q32;q21),+der(18)t(14;18)(q32;q21) | GR (+) | GR (−) | NCVBP, IVAM, ASCT | 7 mo |
17 (19) | 46/F | GL, S, Asc, PE | + | L2 | + | + | + | IgMκ | t(2;3)(p12;q27),add(8)(q24),der(14)t(8;14)(q24;q32),der(18)t(14;18)(q32;q21) | GR (+) | GR (+) | ACVBP, allo-SCT | 3 mo |
18 (20) | 62/F | none | NA | L3 | NA | NA | NA | NA | t(2;8)(p12;q24),t(14;18)(q32;q21) | NA | NA | none | 0.1 mo |
19 (21) | 48/M | GL | – | L2 | NA | NA | NA | NA | t(8;9)(q24,p13),t(14;18)(q32;q21) | NA | NA | R-CHOP | 3.5 mo |
20 (22) | 72/M | H, S | – | L2 | + | NA | + | IgGκ | t(8;9)(q24;p13),t(14;18)(q32;q21) | NA | NA | R-EPOCH | 4 mo |
21 (23) | 71/M | S (mild) | – | L2 | – | + | + | γ | t(1;2)(q22–23;p13),t(8;14)(q24;q32),t(14;18)(q32;q22) | GR (+) | GR (+) | ALL regimen | 2 mo |
22 (24) | 50/F | L (axillary), SC mass | – | L3 | + | + | NA | ND | t(2;3)(p12;q27),t(8;22)(q24;q11),t(14;18)(q32;q21),-17 | fusion (+) | split (+) | ALL regimen | 7 mo |
23 (25) | 29/M | none | – | L3 | + | + | + | NA | +8,t(8;22)(q24;q11),t(14;18)(q32;q21) | NA | split (+) | R-CHOP, R-ICE, R-hyper-CVAD/MA | 5 mo |
24 (25) | 72/M | none | – | L3 | + | + | + | NA | t(8;22)(q24;q11.2),t(14;18)(q32;q21) | NA | NA | R-hyper-CVAD/MA | 11 mob |
25 (25) | 50/F | none | + | L3 | + | + | + | NA | t(8;22)(q24;q11),t(14;18)(q32;q21) | fusion (+) | split (+) | R-hyper-CVAD/MA | 3 mo |
26 (25) | 32/M | L (mesenteric) | + | L3 | + | + | + | NA | t(1;3)(p32;q26.2),t(8;22)(q24;q11),add(14)(q32),t(14;18)(q32;q21) | fusion (+) | split (+) | hyper-CVAD/MA | 8 mo |
27 (25) | 67/M | L (P), small intestine | + | L3 | + | + | + | NA | t(8;14)(q24;q32),der(8)t(8;14)t(14;18)(q32;q21),der(14)t(8;14),+add(14)(q32),i(17)(q10) | fusion (+) | split (+) | R-hyper-CVAD/MA, velcade | 9 mo |
28 (25) | 61/M | L (RP), colon, prostate | + | L3 | NA | NA | NA | NA | t(8;22)(q24;q11),t(14;18)(q32;q21),+der(14)t(14;18) | fusion (+) | NA | hyper-CVAD/MA, MOAP | 9 mo |
29 (25) | 42/F | small intestine, omentum, breast | – | L3 | + | + | + | NA | t(8;14)(q24;q32),t(14;18)(q32;q21),der(17)t(10;17)(q22;q10) | fusion (+) | NA | proMACECytaBOM, CHOP, ESHAP, hyper-CVAD/MA, SCT, RT | 12 mo |
30 (25) | 63/M | testis, lip | – | L3 | + | + | + | NA | NA | fusion (+) | split (+) | hyper-CVAD | 18 mo |
31 (26) | 57/F | none | NA | NA | + | + | – | NA | der(3)t(3;14;?)(q27;q32;?),t(8;14)(q24;q32),der(18)t(14;18)(q32;q21) | fusion (+) | split (+) | CODOX-M/IVAC | 2.5 mo |
32 (26) | 60/M | none | NA | L3 | + | + | + | D | t(2;8)(p12;q24),der(8)t(2;8)(p12;q24),t(14;18)(q32;q21),?i(17)(q10) | fusion (+) | split (+) | hyper-CVAD, CODOX-M | 3 mo |
33 (26) | 63/M | GL, S (mild) | NA | L3 | + | + | + | D | der(3)t(1;3)(q23;q27),t(8;22)(q24;q11),t(14;18)(q32;q21) | fusion (+) | split (+) | CODOX-M/IVAC | 6 mo |
34 (26) | 76/F | none | NA | L3 | – | + | NA | D | t(8;22)(q24,q11),t(14;18)(q32;q21) | fusion (+) | split (+) | VAD | 6 mo |
35 (26) | 59/F | none | NA | L2 | + | NA | NA | NA | t(8;9)(q24;p13),t(14;18)(q32;q21) | fusion (+) | split (+) | ALL regimen | 1.5 mo |
36 (26) | 69/M | L (IP), H | NA | L3 | + | + | + | D | t(14;18)(q32;q21) | fusion (+) | split (+) | ALL regimen | 1.5 mo |
37 (26) | 86/F | none | NA | L2 | + | + | + | ND | add(9)(p13),t(14;18)(q32;q21) | fusion (+) | split (+) | none | 0.5 mo |
38 (27) | 43/F | pancreas | + | L3 | + | + | + | IgMλ | t(8;14)(q24;q32),t(14;18)(q32;q21) | fusion (+) | split (+) | R-CODOX-M/IVAC | 5 mo |
39 (28) | 61/M | GL, S, PE | – | L3 | + | + | + | γ | t(3;5)(q27;q15),t(8;14;18)(q24;q32;q21),+der(8)t(8;14;18),+der(18)t(8;14;18) | fusion (+) | split (+) | R-hyper-CVAD, | NAc |
40 (29) | 42/M | L (IP), S | + | L2 | + | + | + | κ | der(8)del(8)(q12.1q12.3)del(8)(q24.21q24.21)t(8;12)(q24.21;p12.1),der(12)del(12)(p12.1p12.1)t(8;12)(q24.21;p12.1),t(14;18)(q32;q21) | fusion (+) | split (+) | R-CHOP, ALL regimen | 7 mo |
41 (30) | 72/M | bone, liver | + | NA | + | NA | + | NA | t(3;8)(q27;q24),t(14;18)(q32;q21) | fusion (+) | split (+) | ALL regimen | NAc |
42 (31) | 64/M | L (NA) | – | NA | + | NA | + | NA | NA | fusion (+) | split (+) | R-EPOCH | 1.7 moc |
43 (31) | 72/M | L (NA) | – | NA | + | NA | + | NA | t(3;22)(q27;q11.2),t(8;14)(q24;q32),t(14;18)(q32;q21) | fusion (+) | split (+) | R-EPOCH | 1.6 moc |
44 (32) | 74/F | none | + | L2 | + | + | + | κ | –8,del(11)(q23q25),del(13)(q12q14),t(14;18)(q32;q21),+18 | fusion (+) | split (+) | R-CHOP | 3 mo |
45 (32) | 67/M | colon | – | L3 | + | + | −/+ | κ | NA | fusion (+) | split (+) | R-CHOP | 11 mod |
46 (32) | 71/M | L (mediastinal) | – | L3 | + | + | + | κ | der(8)t(8;14;18)(q24;q32;q21),der(14)t(8;14)(q24.1;q32),der(18)t(14;18)(q32;q21) | fusion (+) | split (+) | R-EPOCH, R-ICE, ASCT | 14 mo |
47 (33) | 60/M | GL | NA | L2 | + | + | + | λ | +8,inv(8)(p11.2q24)×2,t(14;18)(q32;q21),-17 | fusion (+) | split (+) | R-hyperCVAD, ofatumumab + EPOCH | 18 mo |
48 (present case) | 69/F | none | – | L2 | + | + | + | IgMκ | add(8)(q24),t(14;18)(q32;q21),-17 | fusion (+) | split (+), EC (+) | R-hyper-CVAD/MA, R-EPOCH | 7 mo |